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Abstract: Inspired by natural TFs, researchers have explored the 
potential of artificial peptides for the recognition of specific DNA 
sequences, developing increasingly sophisticated systems that not 
only display excellent DNA binding properties, but also are endowed 
with new properties not found in their natural counterparts. Herein we 
review some of the developments in the field of artificial peptide-based 
DNA binders, focusing on the supramolecular and molecular design 
aspects of such systems. 
1. Introduction 
Gene transcription in eukaryotic cells is largely controlled by the 
interaction of certain proteins called transcription factors (TFs) 
with specific DNA sequences,1 which modify the basal levels of 
transcription, either enhancing or repressing their expression.2 It 
is known that misregulation of TFs is at the origin of a number of 
diseases, including cancer,3 and thus there is growing interest in 
understanding the molecular basis of specific DNA recognition, as 
well as in developing designed DNA binding agents. Furthermore, 
in addition to the potential applications of such synthetic binders, 
the development of artificial DNA binding agents represents an 
unmet challenge at the crossroads between supramolecular and 
biological chemistry and, beyond its biological relevance, it might 
find future applications in combination with DNA nanotechnology.4 
Most artificial DNA binding agents described to date are small 
molecules, including coordination compounds, as well as small 
organic molecules, which typically bind to the DNA through minor 
groove insertion or intercalation mechanisms, and have been the 
subject of a number of excellent reviews.5 6 In addition to those 
classic DNA-binding agents, researchers, inspired by natural TFs, 
have also explored the potential of designed peptides for the 
specific recognition of DNA, developing increasingly sophisticated 
systems that not only display excellent binding properties, but also 
are endowed with new properties not found in their natural 
counterparts, such as luminescence, photocontrol, nuclease 
activity, or stimuli-responsive binding, which we will review in the 
following pages.7  
1.1. DNA recognition from a supramolecular perspective 
The B-DNA, the most relevant DNA conformation under 
physiological conditions, is characterized by a rather uniform 
right-handed double helix formed by two antiparallel 
oligodeoxyribonucleotide chains, held together by the 
combination of stacking interactions between the base pairs (bps), 
and hydrogen bonds between complementary Watson-Crick 
bps.8  The asymmetry of the deoxyribonucleotides generates two 
grooves in B-DNA double helix: the major groove, which is the 
wide side (~11.7 Å between phosphates across the groove) facing 
away the sugar-phosphate backbone, and the minor groove, 
which is the narrow side (~5.7 Å) of the bps facing towards the 
backbone (Figure 1). Importantly, the B-DNA conformation 
exposes the polar sugar/phosphate backbone while shielding the 
aromatic surface of the bases from the aqueous environment, 
thus giving rise to a monotonous physicochemical landscape, 
where particular base pairs can only be distinguished by relatively 
minor differences in their hydrogen bond donor/acceptor patterns 
at the bottom of the grooves. Thus, for example, A•T/T•A, and 
G•C/C•G bps are degenerate from the minor groove (Figure 1b). 
This configuration increases the challenge for the development of 
specific binders that can distinguish the different base pairs 
against the uniform B-DNA backdrop, and supports the use of 
peptide systems that can replicate the natural TFs.  
Despite the apparent regularity in the B-DNA, it is now 
recognized that the local properties of the B-DNA double helix are 
highly dependent on the base pair sequence, which can be 
considered not only a linear code, but also a structural code that 
influences both the conformation and molecular dynamics.9 For 
example, A•T-rich tracts are known to induce bending of the DNA 
double helix, which is required for the activity of some regulatory 
sites. 10  A•T-rich sequences also display a narrower minor 
groove,11 with a distinct hydration pattern along the floor of the 
groove,12  and is also characterized by a much more negative 
electrostatic potential,13 which can influence both reactivity,14 and 
specific recognition of such sequences.15 
Therefore, specific DNA recognition involves two types of 
interactions: direct readout through the formation of specific 
hydrogen bonds, polar interactions, and hydrophobic contacts 
between amino acids side chains and nucleotide functional 
groups—typically at the exposed edges of the bps in the DNA 
major groove, 16  and indirect readout, which is a more subtle 
mechanism related to the unique physicochemical properties of 
specific DNA sequences, such as readout of the stiffness of DNA 
double helix, its conformational flexibility, our particular 
electrostatic potential.17 These effects can be even observed in 
the DNA binding preferences of small molecules and, for example, 
it has been found that simple intercalators display some sequence 
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selectivity due to the local deformability and conformational 
preferences of particular DNA sequences.18  Evidently, natural 
DNA-binding proteins exploit both strategies to achieve high 
affinity and selectivity. Unfortunately, artificial systems are still 
much more rudimentary, and rational implementation of indirect 
readout in designed systems is still extremely complex. 
 
Figure 1. a) Classic Dickerson-Drew B-DNA dodecamer (PDB: 4C64) 19  
highlighting the major structural elements: sugar-phosphate backbone in orange, 
exposed bp edges in the major groove in dark blue, and exposed edges of the 
bps in the minor groove in light blue. b) structure of the G·C and A·T bps 
showing the pattern of hydrogen bond donors (d) and acceptors (a). 
Recognition of specific DNA sequences in eukaryotes not only 
relies on the readout mechanisms that have been just outlined 
that mediate the interactions between the DNA and each protein, 
but is also orchestrated through specific protein-protein 
interactions that lead to the formation of higher order assemblies 
of multiple TFs that cooperatively bind to the DNA. This allows the 
integration of multiple signaling pathways into complex networks 
of TFs,20 and also expands the number of unique DNA binding 
sites that can be addressed with a given number of TFs, which 
can combine in different ways to bind to composite sequences, 
thus, allowing the complex spatio-temporal control of the >30,000 
human genes with a limited set of 2,000-3,000 TFs.21 Despite the 
relevance of TF cooperativity, the complexities involved in the 
implementation of such effects have hampered the design of 
artificial systems that display some level of cooperativity in their 
DNA binding. 
2. DNA-binding peptides 
2.1. GCN4, the Jack of all trades, master of designed DNA-
binding peptides 
Transcription factors are grouped in families according to the fold 
of their DNA binding domains.22 The GCN4 is an archetypical 
member of the Basic Leucine Zipper (bZIP) family of TFs. As all 
bZIP TFs, GCN4 binds to its target ATF/CREB (5′-ATGAC 
GTCAT-3′) or AP1/GCRE (5′-ATGA(c/g)TCAT-3′) sites as a 
leucine zipper-mediated dimer of uninterrupted α-helices. The 
specific contacts with the edges of the bases exposed in the major 
groove of the DNA take place through the N-terminal basic region 
(br), which folds into an α-helix upon DNA binding (Figure 2).23 
Importantly, it has been shown that monomeric bZIP TFs typically 
display low DNA binding affinity in the µM range,24  and that 
dimerization is required for DNA binding by bZIP proteins, 
because of the high entropic cost involved in the folding of the 
basic region into the α-helical conformation.25  Thus bZIP TFs 
behave as intrinsically disordered proteins that are largely 
unstructured under physiological conditions and display folding 
coupled DNA binding. This allows bZIP proteins to recognize their 
target DNA sites with exquisite selectivity while still forming 
relatively weak, and readily reversible  complexes—in contrast 
with rigid molecules, in which stability of their complexes usually 
correlates with their specificity—and allows increased rates of 
macromolecular associations within complex interaction 
networks.26 
 
Figure 2. a) Structure of the DNA binding domain of the GCN4 TF bound to the 
AP1/GCRE site, highlighting the main structural elements and the key residues 
for specific DNA recognition. The leucine zipper in light green, and the br in blue. 
b) Details of the specific interactions between the GCN4 br with the AP1/GCRE 
half-site. Hydrophobic contacts (Ala238, Ala239, and Ser242) with white dot lines, 
polar/electrostatic contacts (Asn235, and Arg243) with black dot lines. Bases that 
do not participate in specific contacts are outlined as slabs for clarity. 
2.2. Artificial GCN4 peptide dimers 
The structural simplicity of bZIP TFs, added to the wealth of 
functional, biophysical and structural information about GCN4, 
made it into the preferred platform for the development of peptide-
based DNA binders. A key development was reported in 1990 by 






the group of Peter S. Kim, who demonstrated in a seminal paper 
that the complete leucine zipper region of the GCN4 DNA binding 
domain could be replaced by a disulfide bond, and that the 
minimized 34-residue peptide corresponding largely to the GCN4 
between residues 222 and 253 (plus a short Gly-Gly-Cys linker) 
could bind to the natural target site CREB with high (nM) affinity 
at 4 ºC in the form of a disulfide dimer (Figure 3a). As expected, 
the reduced monomeric peptide did not display significant binding 
(Figure 3a).27 Additional studies reported two years later helped 
to identify the sequence of the minimal GCN4 basic region 
fragment that displays specific DNA binding in the form of disulfide 
dimer. Thus, a 23-residue peptide featuring a C-terminal Gly-Gly-
Cys linker (Ac-DPAALKRARNTEAARRSRARKLQ-GGC) binds to 
both ATF/CREB and AP1/GCRE sites in a sequence-specific 
manner with high affinity in its oxidized form as a dimer.28  
 
Figure 3. Schematic representation of the GCN4 dimer showing the helices as 
tubes, and the strategy to generate artificial GCN4 dimers by removing the 
leucine zipper and adding specific linkers between the br fragments. a) P. Kim’s 
disulfide dimer,27,28 b) A. Schepartz’s transition metal coordination compound 
linker,29 c) T. Morii’s chiral linker derived from trans-9,10-dihydrophenanthrene-
9,10-diol,31 d) T. Morii’s supramolecular linker based on a β-
cyclodextrin/adamantane complex,33,34 e) A. Madder’s steroid linker,36,37 f) A. 
Madder’s cyclodextrin dimer,35 g) J. L. Mascareña’s cis/trans azobenzene 
photoswitch linker,40 h) A. Peacock’s metal switch linker,30 i) A. Peacock’s 
photocontrolled anthracene dimer.53 
Following Peter Kim’s work, a number of other groups have 
reported over the years the replacement of the leucine zipper with 
other functionalities. The group of Alanna Schepartz reported in 
1993 the use of a set of transition metal complexes as linkers to 
systematically explore the effect of the geometry of the linker—
and thus, of the relative geometry of the attached basic regions—
on the DNA binding properties of the resulting dimers (Figure 3b). 
Unsurprisingly, they found that dimerization was not sufficient for 
DNA binding, and that the geometry of the metal complexes 
influenced not only the binding affinity of the dimers, but also the 
sequence selectivity. 29  The effect of the geometry in metal 
complexes was also exploited by the group of A. Peacock, who in 
2014 reported a dimer of the GCN4 basic region with a 2,2′:6′,2′′-
terpyridine linker. This linker would undergo a conformational 
change upon metal ion coordination, which in turn would affect 
the relative orientation of the basic regions, and influence the DNA 
binding of the dimer. CD and UV-vis spectroscopy demonstrated 
that coordination of this metal-chelating GCN4 dimer to Cu(II) or 
Zn(II) ions promoted DNA binding (Figure 3h).30 
The influence of geometric effects on the DNA binding 
properties of GCN4 dimers were also studied by T. Morii and Y. 
Sugiura who, based on earlier studies using a 14-residue DNA-
binding peptide derived from the basic region of the helix-loop-
helix transcription factor MyoD, 31  synthesized various GCN4 
dimers connected by C2-symmetric, trans-9,10-dihydro 
phenanthrene-9,10-diol linkers with different chiralities (Figure 3c). 
In this case, the authors found that the stability of the different 
complexes was unaffected by the chirality of the linkers, which 
was consistent with the small effect of the chirality on the relative 
orientation of the attached basic regions. Interestingly, the 
authors also reported dimers of the GCN4 br through the N-
terminus, which recognized altered palindromic DNA sequences 
(5′-TCATC GATGA-3′) in which the polarity of each half-site of the 
parent ATF/CREB) site was reversed.32 
The group of T. Morii was the first to report the use of a non-
covalent linker between GCN4 basic regions; for this, they 
synthesized two peptides by alkylation of a C-terminal Cys 
attached to the core GCN4 br peptide with N-(bromoacetyl)-1-
adamantanemethylamine and mono-6-deoxy-6-iodo-β-
cyclodextrin. Both peptides form a heterodimer, mediated by 
formation of an inclusion complex between β-cyclodextrin, and an 
adamantyl group, which specifically binds to the ATF/CREB (5′-
ATGAC GTCAT-3′) site. The formation of the complex was 
inhibited by the addition of free β-cyclodextrin, once again 
demonstrating that dimerization of the GCN4 basic regions is 
required for specific DNA binding (Figure 3d).33 Interestingly, their 
design relies on the high stability of the complex between 
adamantane derivatives and β-cyclodextrins (KD ≈ 1.3 µM), and 
subsequent studies showed that efficient and cooperative DNA 
binding was still possible if the  original adamantane was replaced 
with norbornyl, KD(Nb/β-CD) ≈ 3.1 µM, or noradamantyl groups, 
KD(NrA/β-CD) ≈ 2.7 µM), but no DNA recognition was observed 
with the cyclohexyl group, which displays a much lower binding 
affinity for β-cyclodextrin with a KD(Ch/β-CD) ≈ 14 µM.34  
A recent paper by A. Madder also makes use of (α,β,γ)-
cyclodextrins for dimerization (Figure 3f). In their case, the 






cyclodextrins were not used as receptors, but as scaffolds for 
covalent attachment of the two GCN4 basic regions. The dimers 
were readily synthesized by a straightforward copper-catalyzed 
azide/alkyne cycloaddition (CuAAC) between the GCN4 br 
peptide bearing a C-terminal propargylglycine, and the 
corresponding diazido cyclodextrins. Curiously, while the  
α-cyclodextrin and β-cyclodextrin GCN4 br dimers display rather 
similar binding affinities for the ATF/CREB site with  
KD(α-CD/DNA) = 50 ± 20 nM and KD(β-CD/DNA) = 30 ± 20 nM, 
the γ-cyclodextrin analog binds with weaker affinity to the same 
DNA with a KD(γ-CD/DNA) = 100 ± 60 nM, and appears to give 
rise to non-specific complexes in Electrophoretic Mobility Shift 
Assays (EMSA), suggesting that the distance between the two 
GCN4 basic regions in the γ-cyclodextrin dimer is not optimal for 
their simultaneous insertion as required in the specific complex.35 
Madder’s group has also reported the application of steroid 
scaffolds for the homodimerization of GCN4 basic regions,36 as 
well as for the heterodimerization of the basic regions of related 
c-Myc/Max basic Helix-Loop-Helix transcription factors, a class of 
TFs related to the bZIP family, containing an additional loop 
between the leucine zipper and the basic region.37 The use of a 
steroidal cholic acid moiety as dimerizer element was justified 
because it provides a rigid, and synthetically-accessible scaffold 
to attach the peptides with reported benefits for improving the cell 
uptake of the conjugates (Figure 3e). 
 
Figure 4. Left: Schematic representation of the cFos/cJun/DNA complex. Right: 
proposed interaction between the cFos-bisbenzamidine hybrid and cJun, 
binding as a heterodimer to a composite DNA site containing the consensus 
recognition sites for cJun and the bisbenzamidine. In contrast with the natural 
complex, the cFos Leucine Zipper is now delivered from the bisbenzamidine the 
minor groove anchor. 
In addition to bZIP dimers that replace the leucine zipper 
dimerization with other functionalities, in 2012 J. L. Mascareñas 
reported a derivative of an heterodimeric cFos/cJun complex in 
which the basic region of the cFos bZIP TF was replaced by a 
small DNA-binding organic molecule.38 Similarly to the role of 
cFos in the natural complex, the bisbenzamidine hybrid of the Fos 
leucine zipper (featuring residues from Arg→Trp157 to Leu179) 
stabilized the cJun/DNA interaction but, in contrast with the 
natural cFos TF, which is bound to the DNA major groove, the 
cFos leucine zipper domain was delivered from the adjacent DNA 
minor groove. Furthermore, the dimer between cJun and the 
cFos-bisbenzamidine conjugate targeted a the composite DNA 
sequence different from the ATF/CREB binding site targeted by 
the natural cJun/cFos heterodimer (5′-ATGAC G AAATTT-3′), 
which contained the natural ATF/CREB half-site (ATGAC) next to 
the A·T-rich site preferred by the bisbenzamidine with an extra G 
as spacer between both recognition elements (Figure 4). 
2.3. Stimuli-responsive DNA-binding peptides 
2.3.1. Light-responsive systems 
Azobenzenes are well-known photoswitches that can interconvert 
between their two isomers: the energetically more stable (about 
10–12 kcal mol–1) trans (E) isomer, and the cis (Z) azobenzene—
by irradiation with light of appropriate wavelength (Figure 5a). 
Thus, irradiation of the π→π* band of the trans state at ~340 nm 
(hυ1) leads to the population of the metastable cis isomer through 
radiationless decay and ultrafast rotation about the N=N bond 
(Figure 5b). Likewise, the cis isomer be interconverted into the 
more stable trans isomer by irradiation of the n→π* at about 450 
nm (hυ2), as well as thermally. Importantly, most azobenzenes 
display a strong overlap in the absorption spectra of their cis and 
trans isomers, which typically leads to incomplete photostationary 
equilibria with about 80% cis or ~95% trans states upon irradiation 
at the π→π* band or n→π* absorption bands, respectively. On 
the other hand, thermal cis→trans equilibration leads to virtually 
complete formation of the trans isomer (Figure 5c).39 
 
Figure 5. a) overview of the trans/cis isomerization of azobenzene showing the 
geometric changes associated with the interconversion between both states; b) 
The potential energy surface of the azobenzene ground state is characterized 
by an asymmetric double well that allows the interconversion of the trans-
azobenzene isomer into the metastable cis-isomer in the ground state by 
irradiation with UV light (hυ1). The low energy barrier between the cis and the 
isomer allows the its thermal conversion into the trans state. Thus, the 
trans→cis interconversion can only be induced by irradiation, whereas the 
cis→trans isomerization can be induced either by irradiation at longer 
wavelength (hυ2), or through a thermal transition; c) Absorption spectra of cis 
and trans azobenzene; the region of the n→π* band at longer wavelength is 
zoomed 8-fold for clarity. Non-radiative processes in b are shown with dashed 
arrows. 






A relevant subset of GCN4 dimers are those whose DNA binding 
can be modulated by light. In the year 2000 the group of J. L. 
Mascareñas reported the first artificial DNA binding peptide that 
displayed light-induced DNA binding.40 Light responsiveness was 
achieved by incorporating an azobenzene unit in the linker 
between two GCN4 basic region peptides. The design takes 
advantage of the large geometrical change experienced by the 
azobenzene upon trans→cis isomerization, so that while the trans 
configuration forces the two GCN4 br away from each other, 
resulting in an unfavorable geometry for simultaneous interaction 
of both peptides in their target sites, the cis- conformation 
presents both basic regions in the appropriate orientation for both 
peptides to interact in their respective half-sites at the same time 
(Figure 3g, and Figure 6). EMSA assays demonstrated that the 
cis isomer binds to the target ATF/CREB site with 60-70 times 
more affinity than the trans isomer. Curiously, the trans→cis 
isomerization can be carried out in the presence of the DNA, but 
in this case the isomerization is about eight times slower than in 
the absence of DNA, and leads to a slightly lower proportion of 
the cis isomer in the photostationary state.  
 
Figure 6. The DNA binding properties of GCN4 dimers featuring an azobenzene 
linker can be modulated by light. Thus, the opposite orientation, and large 
separation between the peptides in the trans azobenzene isomer does not 
support high-affinity DNA binding; a) irradiation with UV light induces the 
isomerization of the azobenzene unit, and b) the resulting cis GCN4 dimer 
presents the right geometry for high-affinity binding as shown in c). Unfolded 
peptides are represented with light-grey thin tubes. 
Before presenting other examples of light-modulated systems we 
must introduce another of the preferred model systems in artificial 
DNA binding peptides, the Homedomain (HD) proteins. HDs are 
highly conserved TFs that play key roles in eukaryotic 
development. The HD DNA binding domain is folded into a helix-
turn-helix motif, with an extended minor groove-binding N-
terminal arm.41 Most of the specific contacts with the DNA are 
made by helix 3 of the protein (h3), which, in the complex with 
DNA, is inserted into the DNA major groove. As in the case of the 
GCN4 and bZIP proteins, the short DNA-contacting helix h3 
isolated from the rest of the protein fails to fold into the α-helical 
conformation and shows negligible DNA binding affinity. The 
engrailed HD Q50K is an altered-specificity Gln50→Lys variant of 
the engrailed HD that preferentially binds to the QRE site 5′-
TAATCC-3′ (while the wild-type engrailed TF binds to the ERE 
sequence, 5′-TAATTA-3′). Furthermore, the engrailed Q50K 
displays higher affinity for the QRE site (KD ≈ 8.8 pM) than the 
wild-type engrailed for its ERE target sequence (KD ≈ 79 pM).42  
After the initial work with azobenzene GCN4 dimers by J. L. 
Mascareñas, the group of G. A. Woolley reported in the year 2005 
an alternative strategy for obtaining light-controlled DNA-binding 
peptides incorporating azobenzene units within DNA basic region 
(Figure 7). 43  Following their work using azobenzenes for 
photocontrolling the α-helical content in short peptides, their first 
design consisted on a 18-residue peptide fragment from the 
recognition helix h3 of the Q50K engrailed homeodomain (Ac-
EAQCKIAAKNARAKCKKA, mutated residues in bold typeface), 
in which residues Ile45 and Ile56 (at i, and i+11 positions) on the 
outer face of the h3 α-helix, were mutated to Cys for introducing 
the 3,3′-bis(sulfo)-4,4′-bis(chloroacetamido)azobenzene cross-
linker. Additionally, a number of residues that do not make direct 
contacts with the DNA were also replaced with Ala in order to 
increase the helical propensity of the peptide, and to avoid 
undesired steric clashes between bulky side chains with the 
azobenzene staple. The thermodynamically-stable trans 
azobenzene displayed significant α-helical content and formed 
stable complexes (KD ≈ 7.5 nM) with the QRE target sequence (5′-
TAATCC-3′). Irradiation with UV light (360 nm) induced the 
trans→cis isomerization of the azobenzene, which significantly 
destabilized the α-helical conformation of h3, and resulted in 
decreased affinity for the DNA (KD ≈ 140 nM).  
 
Figure 7. Miniaturized HD Q50K light-modulated DNA-binding peptide. a) 
Structure of the Q50K engrailed HD highlighting the DNA contacting helix (h3) 
in blue, and the accessory helices h1 and h2 in yellow (PDB: 2HDD). b) The 
light-responsive peptide contains of most of the HD Q50K sequence, and two 
Cys residues at positions 45 and 56 (i, i+11) for stapling with the azobenzene 
unit. The trans azobenzene stabilizes the DNA-binding α-helical conformation, 
while irradiation yields a low-affinity DNA configuration. 
In the following years the group of G. A. Woolley refined their 
designs, 44  and reported modified azobenzene switches with 
improved optical properties for in vivo applications,45 and 2011 
they demonstrated for the first time the application of artificial 
peptides for the photocontrol of protein expression in living cells.46 
The authors focused their attention on the oncoproteins Fos and 
Jun, which are also members of the bZIP family of TFs that bind 
to the AP1/GCRE site as heterodimeric complexes. Their design 
was a modified version of a dominant-negative (DN) peptide 






reported by C. Vinson, 47  which contained an optimized Fos 
leucine zipper dimerization domain for increased affinity for the 
Jun protein,48 and replaced the normal basic region critical for 
DNA binding with an acidic extension that also stabilized its 
complex with Jun, while at the same time prevented the resulting 
heterodimer from binding to the DNA. This DN peptide (AFosW) 
was modified with a 3,3′-bis(sulfonato)-4,4′-bis(chloroacetamido) 
azobenzene cross-link between two Cys residues replacing the 
Asp174 and Thr181 residues in the wild-type Fos leucine zipper 
sequence. The resulting photoisomerizable peptide (XAFosW) 
formed stable heterodimers with Jun when the azo group was in 
the trans configuration, and isomerization of the azobenzene 
crosslink to the cis configuration by irradiation with light at 365 nm 
reduced the stability of the XAFosW/Jun complex by about 10-
fold. The in vivo effect of the XAFosW photoswitch was 
quantitatively studied by measuring the ratios of the activity 
between a luciferase reporter under the control of an AP1/GCRE 
promoter and a β-galactosidase reporter under the control of a 
constitutive rous sarcoma virus (RSV) promoter (pRSV-Gal). 
Thus, XAFosW showed concentration-dependent inhibition 
luciferase activity and, more importantly, a decrease of as much 
as 40% in AP-1 activity upon photo-irradiation. Subsequent work 
has focused on fine tuning these designs, for example by 
identifying the optimal position for introducing crosslinks,49 as well 
as on developing encodable protein chimeras with photoactive 
yellow protein.50 
 
Figure 8. Strategy for electrostatic caging of the DNA binding domain of the 
GCN4 transcription factor. Oligoglutamic (Glu8) domains were attached to the 
N-terminus of the GCN4 br through an orthogonal, photolabile ANP linker, and 
after irradiation, the photoreleased br dimer binds to the DNA. 
In 2012 our own group reported a different approach to obtaining 
light-activated DNA binding peptides. 51   Considering that the 
formation of thermodynamically stable GCN4/DNA complexes 
relies on non-specific electrostatic interactions between 
positively-charged basic residues in the GCN4 basic region with 
the negatively-charged DNA phosphate backbone, 52  we 
envisaged that introducing repulsive interactions with short 
polyanionic tails would suppresses the DNA interaction. 
Furthermore, if the polyanionic tails were attached through a 
photolabile linker, then the interaction between the photoreleased 
GCN4 basic region and the target ATF/CREB DNA could be 
restored by irradiation with light. Thus, P. S. Kim’s GCN4 basic 
region fragment was synthesized with an acidic oligo-glutamic 
domain (Glu8) connected through a photolabile 3-amino-3-(2-
nitrophenyl)-propionic acid (ANP) group. The resulting 
oligozwitterionic basic region containing a short linker with a C-
terminal Cys residue (Glu8-(ANP)-DPAALKRARNTEAARRSRAR 
KLQ-GGC) was dimerized by direct alkylation with 1,4-
bis(bromomethyl)benzene, to yield the desired photoactivatable 
GCN4 derivative (Figure 8). As expected, the electrostatically-
compromised dimer did not display significant DNA binding 
affinity for its target site, and irradiation with UV light irreversibly 
restored the DNA binding of the photoreleased GCN4 br dimer, 
as demonstrated by the appearance of a slow-migrating band in 
gel shift experiments. Circular dichroism assays also confirmed 
the folding of the photoreleased basic region in the presence of a 
short oligonucleotide containing the ATF/CREB target sequence. 
An interesting interplay between the DNA binding of GCN4 
peptides and anthracene photodimerization was described by the 
group of A. Peacock in 2016, when they studied monomeric 
GCN4 basic region peptides modified with anthracene units on 
their C-terminus.53 While anthracene intercalation in the presence 
of non-target DNA sequence proved problematic, circular 
dichroism experiments showed a significant increase in the alpha 
helical content of the peptide upon irradiation in the presence of 
the target ATF/CREB (5′-ATGAC GTCAT-3′) site. Furthermore, 
they found that anthracene photodimerization took place only in 
the presence of such target site, while dimerization of the 
anthracene-basic region peptide was not observed when 
irradiation was made in the presence of half-site or random DNAs. 
As expected from the previous work with GCN4 dimers, the 
resulting photocrosslinked dimer displayed stronger DNA binding 
than the monomeric peptides. 
 
Figure 9. Photocleavable (2,2′-bipyridyne)Ru(II) linkers in bZIP basic region 
dimers (either GCN4 homodimers or C/EBP-GCN4 heterodimers). The high-
affinity, specific DNA complex can be disassembled by irradiation with long-
wavelength light. The different species resulting from the asymmetric photolysis 
can be identified by HPLC-MS (right). 
One of the major problems associated with the application of 
photocontrolled peptides in vivo is the short wavelengths at which 
the photoswitches and caging groups respond, typically below 
400 nm, which have poor tissue penetration, and are readily 
absorbed by other biomolecules. In this context, photolabile 






bisbipyridyl ruthenium(II) complexes have been explored as 
alternative photoactive components due to their advantageous 
spectroscopic properties, such as long wavelength of photolysis 
and high uncaging quantum yields. Thus, we reported in 2014 the 
use of ruthenium bipyridyl complexes as photocleavable 
dimerizers of  cysteine-containing transcription factor fragments. 
More specifically, we reported the synthesis of a generally 
applicable cis-bromoalkyl-(2,2′-bipyridine)Ru(II) biselectrophilic 
reagent, which was derivatized to obtain homodimeric GCN4 br 
dimers, similar to those previously described in the 90s by A. 
Schepartz, as well as C/EBP-GCN4 heterodimers. In both cases 
the dimeric constructs displayed good DNA binding affinity and 
selectivity for their respective target site. Moreover, their DNA 
binding could be suppressed by irradiation at 455 nm with a LED 
source and photolysis of the ruthenium dimerizer (Figure 9).54  
Ruthenium compounds have been used as photolabile 
protecting groups to control the DNA binding of small peptides.55 
In 2015 we reported the synthesis of a light-sensitive  histidine  
building  block  for Fmoc/tBu solid-phase peptide synthesis in 
which the imidazole side chain is protected with a ruthenium 
complex. This building block was used for the synthesis of a 
photoactivatable Arg-Gly-His tripeptide (RGH), which has been 
shown to be an efficient metal-chelating sequence (KD < 10–16 M), 
endowed with DNA binding and endonuclease properties in the 
presence of Ni(II) ions and oxidizing agents.56 We demonstrated 
that the caged His analog was unable to coordinate the Ni(II) 
required form the catalytic metallopeptide. Moreover, we also 
showed that DNA binding and nuclease activity could be 
recovered upon irradiation at long wavelength (455 nm LED), and 
uncaging of the His residue (Figure 10). 
 
Figure 10. caged RGH peptide does not bind to Ni(II). Irradiation with red ligt at 
455 releases the metal-chelating peptide, which folds and binds into the DNA 
minor groove, where it can exert its nuclease activity. 
2.3.2. Metal coordination and dynamic DNA-binding 
In contrast with the static designs—i.e. insensitive to external 
inputs—that represent the majority of DNA-binding peptides 
reported until now, one of the first steps into the development of 
stimuli-responsive peptides derived from transcription factors was 
reported by Y. Sugiura in 2004.57 In this work, the Fos leucine 
zipper is modified with a pair of metal-chelating iminodiacetic acid 
derivatives of lysine (Ida) at positions i, and i+2. Incubation with 
Fe(III), and coordination of this metal ion, destabilizes the alpha 
helical conformation of the Fos(Ida)2 peptide, thus preventing the 
formation of the heterodimer with the Jun leucine zipper. 
Unfortunately, the authors did not pursue this concept for 
modulating the DNA binding of the Fos-Jun network of homo- and 
heterodimers. In a related work, a successful DNA binding switch 
in response to a metal ion was reported by the group of Futaki in 
2009, who expressed a recombinant GCN4 DNA binding domain 
(56-mer peptide) featuring two pairs of Cys residues at relative i 
and i+2 positions in the leucine zipper domain. These residues 
were selectively derivatized using N-(2-
tosylthioethyl)iminodiacetic acid to turn them into metal-chelating 
residues. The resulting tetra-Ida-modified GCN4 DNA binding 
domain displayed significant helical structure, and high DNA 
binding affinity for the AP1/GCRE site (KD = 22 ± 3.0 nM) similar 
to that of the natural GCN4 dimer (KD = 15 ± 2.6 nM). Addition of 
excess of Co(II) to this metal-binding peptide induced a 33% 
decrease in its helical content, and also a drastic reduction in its 
DNA binding affinity (KD > 1.0 µM). As expected, addition of EDTA 
to the mixture—and sequestering of the Co(II) ions—resulted in 
the recovery of the initial binding affinity in absence of the metal 
ion (KD = 22 ± 1.1 nM). Curiously, the switching effect was not 
observed in control peptides that contained a single pair of Ida 
residues in their leucine zipper domains.58  
The effect to metal ion coordination can be combined with 
other orthogonal signals, such as redox processes to yield more 
complex designs that respond to multiple stimuli. This was 
exemplified in 2013, when we described the synthesis of a GCN4 
basic region fragment that contained a redox-sensitive Cys 
residue on its N-terminus, and a metal-chelating 5,5′′-dimethyl-
2,2′:6′,2′′-terpyridine ligand orthogonally attached to a C-terminal 
Lys231 residue (Cys)br(tpy). 59  Incubation of this peptide with 
Ni(ClO4)2 in the presence of the target ATF/CREB site (5'-ATGA 
CG TCAT-3') gave rise to slow-migrating bands consistent with 
the formation of a specific peptide-DNA complex between the 
nickel-mediated dimer of the basic region and the DNA. Under the 
same conditions, the peptide did not display significant affinity for 
the inverted sequence (5'-TCAT CG ATGA-3'). In contrast, the N-
terminal disulfide dimer formed by oxidation of the peptide with 
DTNB, 5,5'-dithiobis-(2-nitrobenzoic acid), only showed binding to 
the inverted site (Figure 11). As expected, reduction of the 
disulphide dimer by treatment TCEP (tris(2-carboxyethyl) 
phosphine) recovered the monomeric (Cys)br(tpy) peptide, and 
promoted the disassembly of the complex with the inverted 
sequence. Curiously, the disulfide dimer required the presence of 
Ni(II) ions to bind to its target inverted site. 
 







Figure 11. Dynamic DNA binding selection to multiple sites. The reduced 
monomeric (Cys)br(tpy) peptide in the presence of Ni(ClO4) binds to the 
consensus DNA (5'-ATGA CG TCAT-3') as a metal-mediated homodimeric 
complex (KD ≈ 670 nM at 4ºC). Oxidation of the N-terminal Cys side chain with 
DTNB yields the N-terminal disulfide dimer, which binds to the inverted polarity 
sequence 5'-TCAT CG ATGA-3' in the presemnce of Ni(II) salts (KD ≈ 758 nM). 
The original C-terminal complex can be recovered by reduction with TCEP 
(tris(2-carboxyethyl)phosphine). In both cases the binding of the peptides for 
their non-target DNAs were in the µM range). 
De novo designed DNA-binding metallopeptides are relatively 
uncommon, and typically contain an octahedral metallo-
intercalator complex that binds in the DNA major groove attached 
to a short peptide that modulates its DNA recognition or 
internalization properties. Prominent examples of this general 
design have been reported by J. Barton since the 90s, when they 
described conjugates between short 13-mer peptides and 
photoactive [Rh(phi)2(phen′)]3+ (phi = 9,10-phenanthrenequinone 
diimine; phen′ = 5-(amidoglutaryl)-1,10-phenanthroline) 
complexes. The coordination compounds intercalate through the 
DNA major groove with high affinity, and upon photoactivation, 
induce DNA strand scission. The DNA site specificity was 
dependent on the sequence of the appended peptide, and the 
authors found that a single glutamate at position was essential in 
directing DNA site-recognition to the sequence 5′-CCA-3′.60 Later 
examples demonstrated the general applicability of this strategy 
by inserting different peptides with alternative sequence 
preferences, such as the DNA  recognition helix of the phage 434 
repressor (preferentially targeting the sequence 5′-ACAA-3′).61 
Related designs featured α-helical metallopeptides with nuclease 
activity tethered to the [Rh(phi)2(phen′)]3+ complex. Thus, the 
peptide sequence DPDELEHAAKHEAAAK, contains two His 
residues (in bold) in positions i, i+4 that create a zinc coordination 
site on one face of the α-helix. A number of residues were 
included in the sequence to increase the α-helical content, such 
as a C-terminal E-K salt bridge, and a number of Ala residues. 
The resulting metallointercalator-peptide nuclease chimera was 
found to convert a supercoiled pBR322 DNA plasmid to both the 
nicked and linear forms. Control experiments did not show any 
cleavage when the DNA was incubated with the unmodified 
rhodium intercalator, or the peptide nuclease without the 
intercalator, thus demonstrating the cooperative nature of the 
construct. 62  Similar effects were observed with rhodium 
conjugates with metallopeptide hairpin nucleases.63 
A relatively recent example of these metallointercalator-
peptide hybrids explored the effect of the peptide sequence in the 
internalization and intracellular localization.64  In this study the 
[Ru(phen)(bpy′)(dppz)2]2+ complex (bpy′ = 4-(3-carboxypropyl)-4′-
methyl-2,2′-bipyridine) was attached to a well-known (D)-
octaarginine (arg8) peptide transporter, and to that same peptide 
modified with a fluorescein tag (arg8-Flu) (Figure 12). Interestingly, 
they found that while the simple Ru-[arg8] conjugate was 
internalized by endocytosis, and remained in the cytoplasm in a 
punctuate pattern, the Ru-[arg8]-Flu derivative was readily 
internalized into the cell nucleus under the same conditions for 
which the complex without fluorescein was excluded. This 
difference in intracellular localization is consistent with other 
studies that demonstrate the role of charge and hydrophobicity 
compensation in peptide transporters.65 This result demonstrates 
the potential role of the peptide appendages not only in the DNA 
recognition process, but also for the modification of other 
properties, such as cell transport. 
 
Figure 12. [Ru(phen)(bpy′)(dppz)2]2+ arg8 conjugates display different transport 
properties depending on their N-terminal modification with the hydrophobic 
fluorescein fluorophore. [Ru(phen)(bpy′)(dppz)2]2+-arg8 is internalized in 
endosomes, while the analog featuring an N-terminal fluorescein is efficiently 
transported into the cell nucleus. 
In addition to the modification of discrete metallointercalators, 
peptides have also been used as integral structural elements in 
de novo DNA binding metallopeptides without any resemblance 






to natural transcription factors. In this context, in 2014 we 
described the application of solid-phase peptide synthesis 
methodology to assemble peptide ligands as precursor of metal 
helicates, which are chiral metal complexes constituted by two (or 
more) metal ions. These metalocylinders have been shown to 
target unusual three-way DNA junctions, 66  and indeed, upon 
incubation with Fe(II), the peptide precursors enantioselectively 
assembled into ΛΛ- or ΔΔ-dimetallic helicates (Figure 13) that 
displayed high affinity for three-way DNA junctions (KD ≈ 3.47 µM 
for the ΛΛ- isomer, and 13.59 µM for the ΔΔ-helicate). In contrast, 
the binding of these species to double-stranded DNA was rather 
weak (KD ≈ 40 µM for A·T-rich oligonucleotides, and  KD ≈ 100 µM 
for G·C-rich oligos). Following the same methodology, our group 
has recently described a new family of oligonuclear Ru(II) and 
Ir(III) polypyridyl organometallopeptides that exhibit exhibit  high  
DNA  binding  affinity in the low nanomolar range, sequence  
selectivity,  and  high cytotoxicity against set cancer cell lines.67 
 
Figure 13. Solid phase peptide synthesis of the peptide helicates. Introduction 
of (L)-Pro or (D)-Pro residues in the loops selects a particular supramolecular 
chirality (ΛΛ- or ΔΔ-, respectively) in the final helicates. Bottom: Proposed 
structure of the peptide helicate bound to the center of a three-way DNA junction. 
DNA is only represented as ribbons for clarity. 
2.3.3. Artificial GCN4 basic region monomers 
Monomeric GCN4 basic regions do not bind to their target DNA 
half-site with high affinity due to the entropic cost associated to 
the folding of the peptide chain into the appropriate α-helical 
conformation, but residue grafting is a powerful strategy to obtain 
stabilized α-helices and thus obtain high-affinity DNA binding 
monomeric GCN4 peptides.68 In this approach, selected residues 
that create the desired binding epitope are inserted (grafted) into 
a stable three-dimensional peptide scaffold. The group of A. 
Schepartz described in 1999 successful application of this 
strategy to obtaining high-affinity monomeric DNA-binding 
peptides.69 Their design involved the introduction of the GCN4 
residues mediating DNA binding in the basic region into the α-
helix of the avian pancreatic polypeptide (aPP), a stable 
miniprotein consisting of a single α-helix stabilized by hydrophobic 
interactions with a type II polyproline helix. The resulting chimera 
was capable of recognizing the half site of the GCN4 DNA target 
sequence (5’-ATGA-3’) with a KD of 1.5 nM under physiological 
ionic strength. However, the mutations introduced in the aPP 
sequence for achieving DNA binding resulted in the disruption of 
the aPP hydrophobic core, and reduced structural stability of the 
construct. Further refinements of this initial binder using phage 
libraries resulted in a new peptide with extraordinary DNA affinity 
at 4 ºC (KD ~ 23 pM), which even retained high affinity at 25 ºC 
(KD ~ 1.6 nM).70 Following the successful implementation of the 
grafting strategy to the synthesis of simplified versions of a bZIP 
transcription factor (GCN4), the Schepartz group demonstrated 
the versatility of this approach by obtaining miniature 
homeodomain proteins, again by dissecting the key DNA 
contacting residues and introducing them into the structure of the 
versatile aPP peptide scaffold.71 
The group of G. L. Verdine demonstrated in 1995 that it was 
possible to drive specific DNA recognition by a monomeric GCN4 
basic region if the peptide was delivered into the major groove 
intramolecularly.72 Attaching the GCN4 br to the DNA significantly 
increased its effective concentration, and reduced the entropic 
loss associated with intermolecular binding, thereby allowing the 
formation of the desired (intramolecular) complex. The design 
required a Gly-Gly-Cys connector to connect the C-terminus of 
the GCN4 br to an Adenine nucleotide immediately 5′ to the 
AP1/GCRE half-site (5′-A(c)TCAT-3′, modified base in bold) 
through a disulfide bond. 
Taking the concept of intramolecular delivery for specific DNA 
binding one step further, the group of J. L. Mascareñas reported 
in 2001 the synthesis of conjugates between the GCN4 br and a 
small minor groove binding molecule that was capable of 
sequence-specific DNA recognition. 73  The role of the minor 
groove binding agent (a distamycin derivative) was analogous 
that of the disulfide linker in the original Verdine’s intramolecular 
complex: to act as a supramolecular anchor that, upon binding to 
its target sequence in the DNA minor groove (5′-AAATT-3′), would 
deliver the GCN4 br into its binding site—the ATF/CREB half-site 
(5′-gTCAT-3′)—in the adjacent major groove. Based on the X-ray 
structures of the GCN4 dimer and distamycin bound to their 
respective DNA sites,74 the authors built a hypothetical model of 
the simultaneous interaction of the GCN4 basic region and the 






small DNA binding agent bound to contiguous sites, which 
allowed the identification of Arg245 as the ideal position for 
installing short aminoalkyl linkers connecting with the distamycin 
bound to the adjacent minor groove. Unlike isolated GCN4 basic 
regions, the resulting conjugate displayed tight (low nM affinity at 
4 ºC) and selective binding to a composite site containing the 
consensus sequences for both the GCN4 and the distamycin 
derivative (5′-gTCAT-AAATT-3′). As expected, control 
experiments with DNAs lacking the target sequence of the 
distamycin anchor did not show binding of the GCN4-distamycin 
hybrid to the DNA, thus confirming the key role of the accessory 
interactions established by the distamycin analog in the minor 
groove for stabilizing the complex. 
Following that initial report, the group of J. L. Mascareñas 
demonstrated that the conjugation strategy could be generally 
applied for the stabilization of TF fragments, describing a variety 
of peptide hybrids that recognized extended sites containing the 
sequence of both the peptides and the distamycin. Thus, for 
example, the DNA binding helix of the Skn-1 transcription factor 
could be conjugated through its Lys232 side chain to distamycin, 
and the resulting hybrid selectively bound to the site 5′-AAAA-
TCAT-3′.75 Importantly, this strategy could also be extended to 
other transcription factor families, so that conjugation to 
distamycin restored the DNA binding properties of a fragment of 
the GAGA zinc finger transcription factor, which selectively bound 
to the composite sequence 5′-TTTT-GAGAG-3′ containing an 
A·T-rich site for distamycin binding (5′-TTTT-3′) next to the GAGA 
TF consensus binding sequence (5′-GAGAG-3′). 76  Similar 
conjugates with GCN4 and GAGA fragments, and even with 
homeodomain fragments, 77  were also described using 
bisbenzamidines as minor groove binding ligands, 78  further 
demonstrating the modular nature and general applicability of this 
strategy for obtaining sequence-selective DNA binding peptides 
derived from transcription factors (Figure 14).79  
The thermodynamic stabilization of FT fragments to obtain 
high-affinity DNA binders does not require the use of artificial DNA 
binding agents such as distamycin or bisbenzamidines as 
described before, but can also be achieved with fully peptidic 
anchors. The AT-Hook is a short cationic peptide (RKPRGRPKK) 
found in eukaryotic HMG-I(Y) nuclear proteins.80 Although AT-
Hooks bind to their target DNA sites with poor affinity (in the 
millimolar range), 81  HMG-I(Y) proteins exploit the cooperative 
effect of three AT-Hook repeats to achieve high DNA binding 
affinity. 82  NMR and crystallography studies have provided a 
detailed structural picture of the interaction of the AT-Hook with 
the DNA, and have shown that its central RGR core is deeply 
inserted into the minor groove in an extended conformation, while 
the various lysines in the sequence introduce additional 
electrostatic contacts with the phosphates of the DNA 
backbone.83 We recently reported the use of an AT-Hook as minor 
groove binding element in combination with the GCN4 br. The 
peptidic nature of the AT-Hook allows the straightforward 
synthesis of the GCN4 br/AT-Hook chimera following exclusively 
solid-phase peptide synthesis methods, and the lower DNA 
binding affinity of the AT-Hook compared to bisbenzamidines or 
distamycin results in better selectivity profile.84 
A related example, recently published by the group of S. Roy 
in 2017, further demonstrates that the combination of short minor 
groove anchors and TF fragments is a robust approach to 
developing sequence-specific DNA binding peptides. In their work, 
S. Roy’s group used a short minor groove-binding tail from the 
Serum Response Factor (SRF) in combination with the DNA-
binding helix of Elk1 to yield a dominant negative of the two 
transcription factors, which upon DNA binding to the DNA 
upregulate the oncogene cFos.85 The authors explored different 
linkers, such as GlyProGlyProGly, Ahx3 (Ahx = aminohexanoic 
acid), Gly-Ahx3, Gly2-Ahx3, and Gly3-Ahx3, between both DNA 
binding units, and studied as well conformationally-stabilized 
versions of the DNA contacting helix containing Aib residues, 
which are known to stabilize the α-helical conformation by 
restricting the available backbone conformations.86 Importantly, in 
contrast with other conjugates that appear to get stuck inside 
endosomes upon internalization, the Gly2-Ahx3 chimera was 
readily internalized into the nuclei of A549 lung adenocarcinoma 
cells, and induced a specific response, down-regulating its 
targeted gene. 
 
Figure 14. Proposed models of TF fragments stabilized by small minor groove 
binding agents. a) Original GCN4 basic region conjugate with distamycin,73 b) 
GAGA/distamycin conjugate,76 c) GCN4/bisbenzamidine hybrid, d) 
GAGA/bisbenzamidine hybrid; e) GCN4/AT-Hook chimera,84 f) engrailed 
homeodomain/bisbenzamidine conjugate. 






In an alternative approach to dominant negative DNA-binding 
peptides we described the synthesis of a dominant negative of the 
oncogenic c-Jun protein as an inactive complex by forcing its 
heterodimerization with a c-Fos-DNA conjugate. 87  This 
oligonucleotide-peptide receptor was based on the X-ray 
structure of the the c-Fos/c-Jun heterodimer bound to the AP1 
site,88 and included a fragment of the c-Fos leucine zipper (Arg158 
to Lys192) to induce c-Jun dimerization, attached to the 5′ end of a 
short oligonucleotide (5′-TGACTCATCCATTGCGCG-3′) 
containing the AP1 half-site (in bold) for c-Jun binding. The 
oligonucleotide provides increased affinity and selectivity for c-
Jun, as demonstrated by its tight binding constant (KD ≈ 200 nM) 
that allowed it to efficiently compete with the natural c-Fos and 
disassemble the natural c-Fos/c-Jun heterodimer bound to the 
DNA. 
In summary, since the early 90s a number of groups have 
developed efficient strategies for the development of miniaturized 
versions of transcription factors, these efforts have not only 
expanded the repertoire of DNA binding motifs, but also produced 
new systems with unique properties not found in natural systems, 
such as light-activation. The progress in the field, however, has 
been relatively slow partly due to our rudimentary understanding 
of peptide and protein folding, and still limited computational 
methods for efficient in silico selection in the context of peptide-
DNA interactions. On the other hand, while many systems have 
been described, most of them are isolated and static complexes, 
but complex and dynamic systems involving more than one DNA 
binding partner are still largely unexplored, and will probably be 
the focus of future development. Finally, limited by their inherent 
internalization problems, these peptide systems have not yet 
found real biological applications, but new developments in 
delivery platforms and strategies will open the way for their use in 
living systems, exploiting their full potential as artificial TFs for 
controlling gene expression.89 
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